Chemotherapy for Secondary Neoplastic Meningitis
Name of the Trial
Phase I Study of Intrathecal Gemcitabine in Patients with Neoplastic Meningitis Secondary to Leukemia, Lymphoma, or a Solid Tumor (TCCC-H-10564). See the protocol summary.
Dr. Lisa Bomgaars, Texas Children's Cancer Center.
Why This Trial Is Important
Neoplastic meningitis is a condition in which cancer cells spread into the membranes surrounding the brain and the spinal cord (the meninges). Often, the condition is associated with cancer that has spread from tumors elsewhere in the body. Neoplastic meningitis is difficult to treat because chemotherapy drugs injected intravenously often do not reach high enough concentrations in the meninges to be effective. Consequently, chemotherapy for neoplastic meningitis is often given intrathecally, injected into the fluid-filled space between the meninges.
This study seeks to determine whether the drug gemcitabine (Gemzar®) may be effective in treating neoplastic meningitis caused by the spread of a primary leukemia, lymphoma, or solid tumor. Gemcitabine is active against many of types of cancer that tend to spread to the meninges, and may prove effective in treating secondary neoplastic meningitis.
"The agents available to treat neoplastic meningitis are quite limited," said Dr. Bomgaars. "Gemcitabine is an agent that works differently from other treatments for this condition. If effective, it will be a welcomed new option for patients fighting neoplastic meningitis."
This clinical trial is no longer accepting patients. To locate other trials for metastatic cancer, search the NCI database of clinical trials or call the NCI's Cancer Information Service (CIS) at 1-800-4-CANCER (1-800-432-6237). The call is toll free and completely confidential.